Safety, tolerability and immunogenicity of an active anti-Abeta40 vaccine (ABvac40) in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase I trial
Lacosta AM, Pascual-Lucas M, Pesini P, et al. Alzheimers Res Ther. 2018; 10:12.
Clinical utility of an antibody-free LC-MSmethod to detect brain amyloid deposition in cognitively unimpaired individuals from the screening visit of the A4 Study
Jose Antonio Allué, et al. Alzheimer’s Dementia Diagnosis Assessment Disease Monitoring 2023
Clinical performance of an antibody‑free assay for plasma Aβ42/Aβ40 to detect early alterations of Alzheimer’s disease in individuals with subjective cognitive decline
Pascual-Lucas M, Allué JA, Sarasa L et al.
Alzheimer’s Research & Therapy 2023; 15:2
Comparative performance of plasma Aβ42/Aβ40 and p‐tau181 for the detection of early brain amyloid deposition in individuals with subjective cognitive decline.
Poster presentation CTAD 2022—ABtest MS FACEHBI Cohort
Pascual-Lucas M, Allué JA, Sarasa L et al.
Plasma Aβ42/Aβ40, measured by a novel mass spectrometric method, identifies early amyloid deposition in individuals at risk of Alzheimer’s disease (FACEHBI Cohort)
Characterization of pre-analytical sample handling effects on a panel of Alzheimer’s disease–related blood-based biomarkers: Results from the Standardization of Alzheimer’s Blood Biomarkers (SABB) working group.
Verberk IMW, Misdorp E, Koelewijn J et al.
Alzheimers Dement 2022; 18:1484-1497.
Correlations between plasma and PET beta-amyloid levels in individuals with subjective cognitive decline: the Fundació ACE Healthy Brain Initiative (FACEHBI)
De Rojas I, Romero J, Rodríguez-Gómez O, et al. Alzheimers Res Ther. 2018; 10:119.